We found for
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
![Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers](https://www.ohe.org/wp-content/uploads/2022/01/CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape.jpg)
It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?
![It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?](https://www.ohe.org/wp-content/uploads/2022/02/Towse-Fenwick-post-review-final-v2-01.png)
Key Factors on How to Procure, Pay, Distribute and Use Vaccines for COVID-19: A European Perspective
![Key Factors on How to Procure, Pay and use Vaccines for COVID-19 2-01](https://www.ohe.org/wp-content/uploads/2021/11/Key-Factors-on-How-to-Procure-Pay-and-use-Vaccines-for-COVID-19-2-01.png)
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment
![WHO-cancer-medicines-rebrand](https://www.ohe.org/wp-content/uploads/2019/05/WHO-cancer-medicines-rebrand.png)
Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates
![Value, Access, and Incentives for Innovation - Policy Perspectives on Alternative Models for Pharmaceutical Rebates](https://www.ohe.org/wp-content/uploads/2019/03/Value-Access-and-Incentives-for-Innovation-Policy-Perspectives-on-Alternative-Models-for-Pharmaceutical-Rebates.jpg)
Review of CRA’s Report “Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe”
![Consulting Report for EFPIA Cover Image](https://www.ohe.org/wp-content/uploads/2018/01/Consulting-Report-for-EFPIA-Cover-Image.jpg)